Moreno, Victor http://orcid.org/0000-0001-6099-4236
Vieito, Maria
Sepulveda, Juan Manuel
Galvao, Vladimir
Hernández-Guerrero, Tatiana http://orcid.org/0000-0003-3459-871X
Doger, Bernard
Saavedra, Omar
Carlo-Stella, Carmelo
Michot, Jean-Marie
Italiano, Antoine http://orcid.org/0000-0002-8540-5351
Magagnoli, Massimo
Carpio, Cecilia
Pinto, Antonio
Sarmiento, Rafael
Amoroso, Barbara
Aronchik, Ida
Filvaroff, Ellen
Hanna, Bishoy
Wei, Xin
Nikolova, Zariana
Braña, Irene
Funding for this research was provided by:
Celgene
Celgene, a Bristol Myers Squibb Company
Article History
Received: 14 January 2022
Accepted: 23 February 2023
First Online: 13 March 2023
Competing interests
: V.M. has received consulting fees from Bristol Myers Squibb, Basilea, Bayer, Janssen, Nanobiotix, Pieris Pharmaceuticals, Regeneron/Sanofi, and Roche, and honoraria from Bristol Myers Squibb and Bayer. M.V. has received personal fees from Roche, EMD Serono, and TFS. J.M.S. has received personal fees and non-financial support from Celgene (a Bristol Myers Squibb Company), AbbVie, and Astellas, non-financial support from Ipsen, and research grants from Pfizer and IDP Pharma. J.-M.M. has received research grants from Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi, non-financial support from Bristol Myers Squibb, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, MedImmune, Merck, NH TherAguix, Pfizer, and Roche, and other support from Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Merck, Merck Sharp & Dohme, Pfizer, and Regeneron. A.I. has received consulting fees from Epizyme, Lilly, Merck Sharp & Dohme, Novartis, Pharmamar, and Roche, and received research grants from Bristol Myers Squibb, AstraZeneca, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pharmamar, Pfizer, and Roche. M.M. has received honoraria from AstraZeneca and Sanofi. C.C. has received consulting fees for acting in an advisory role from Bristol Myers Squibb, Regeneron, Novartis, and Takeda. A.P. has received honoraria from Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Helsinn Healthcare, Janssen, Celgene, Gilead Sciences, Incyte, Servier, Merck Sharp & Dohme, and Takeda. I.B. has received personal fees from Bristol Myers Squibb, AstraZeneca, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Rakuten Aspyrian, Roche, and research funding from Bristol Myers Squibb, AstraZeneca, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Rakuten Aspyrian, Roche, Celgene, GlaxoSmithKline, Incyte, Janssen, Kura, Novartis, Pfizer, Shattuck Labs, and VCN Biosciences. V.G., T.H.-G., B.D., O.S., and C.C.-S. have no conflicts of interest to disclose. R.S., B.A., and Z.N. are employed by the Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company. E.F., B.H., and X.W. are employed by Bristol Myers Squibb. B.H., E.F., R.S., X.W., and Z.N. hold Bristol Myers Squibb stock. I.A. was employed by Bristol Myers Squibb at the time of the study.